Iovance Shares Shares Get After-Hours Boost From FDA Approval
27 May 2023 - 9:05AM
Dow Jones News
By Mary de Wet
Iovance Biotherapeutics shares rose 15% in after-hours trade
Friday after the company's biologics license application for
lifileucel to treat advanced skin cancer was approved by the Food
and Drug Administration.
The stock was at $8.67 after closing at $7.55 in regular trade.
Shares are up 18% for the year.
"The FDA is not currently planning to hold an advisory committee
meeting to discuss this application and, after a preliminary
review, has not at this time identified any potential review
issues," the San Carlos, Calif.-based company said.
Lifileucel is a tumor infiltrating lymphocyte therapy intended
for patients with advanced melanoma who progressed on or after
prior anti-PD-1/L1 therapy and targeted therapy, Iovance said.
There are no FDA-approved therapies to treat these patients, the
company said.
With the biologics license application approved, Iovance can get
a license to market lifileucel in the U.S.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
May 26, 2023 18:50 ET (22:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024